Susquehanna Fundamental Investments LLC Takes $3.36 Million Position in Glaukos Corporation $GKOS

Susquehanna Fundamental Investments LLC bought a new position in shares of Glaukos Corporation (NYSE:GKOS) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 24,049 shares of the medical instruments supplier’s stock, valued at approximately $3,361,000.

Several other institutional investors have also added to or reduced their stakes in the company. AQR Capital Management LLC lifted its holdings in shares of Glaukos by 2.6% during the first quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock worth $766,000 after buying an additional 198 shares in the last quarter. Jones Financial Companies Lllp grew its stake in shares of Glaukos by 1,405.9% in the first quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock valued at $252,000 after acquiring an additional 2,390 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Glaukos by 41.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock worth $22,636,000 after acquiring an additional 67,668 shares during the period. M&T Bank Corp acquired a new stake in Glaukos in the 2nd quarter worth about $203,000. Finally, Gamco Investors INC. ET AL raised its stake in Glaukos by 10.7% in the 2nd quarter. Gamco Investors INC. ET AL now owns 8,001 shares of the medical instruments supplier’s stock worth $826,000 after purchasing an additional 773 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on GKOS shares. Wells Fargo & Company increased their price target on Glaukos from $138.00 to $178.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. Stifel Nicolaus upped their target price on Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. UBS Group assumed coverage on Glaukos in a report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 target price on the stock. Citigroup raised their price target on Glaukos from $175.00 to $188.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Finally, Needham & Company LLC upped their price objective on shares of Glaukos from $150.00 to $201.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and a consensus target price of $178.08.

Insider Buying and Selling

In other Glaukos news, Director Gilbert H. Kliman sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total transaction of $475,000.00. Following the completion of the transaction, the director owned 37,406 shares in the company, valued at approximately $7,107,140. This trade represents a 6.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Leana Wen sold 525 shares of the business’s stock in a transaction on Friday, July 31st. The shares were sold at an average price of $167.63, for a total transaction of $88,005.75. Following the completion of the transaction, the director owned 21,092 shares in the company, valued at approximately $3,535,651.96. The trade was a 2.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 113,025 shares of company stock valued at $19,600,006. Company insiders own 5.90% of the company’s stock.

Glaukos Stock Performance

Shares of Glaukos stock opened at $179.45 on Tuesday. The firm has a market capitalization of $10.58 billion, a P/E ratio of -55.22 and a beta of 0.78. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $191.62. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. The company’s 50 day moving average price is $163.60 and its two-hundred day moving average price is $134.57.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. The business had revenue of $185.61 million during the quarter, compared to analysts’ expectations of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The business’s revenue for the quarter was up 49.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.24) EPS. On average, equities analysts forecast that Glaukos Corporation will post -0.32 earnings per share for the current fiscal year.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.